A Mathematical Model of Immune-System-Melanoma Competition

We present a mathematical model developed to reproduce the immune response entitled with the combined administration of activated OT1 cytotoxic T lymphocytes (CTLs) and Anti-CD137 monoclonal antibodies. The treatment is directed against melanoma in B16 OVA mouse models exposed to a specific immunotherapy strategy. We model two compartments: the injection point compartment where the treatment is administered and the skin compartment where melanoma tumor cells proliferate. To model the migration of OT1 CTLs and antibodies from the injection to the skin compartment, we use delay differential equations (DDEs). The outcomes of the mathematical model are in good agreement with the in vivo results. Moreover, sensitivity analysis of the mathematical model underlines the key role of OT1 CTLs and suggests that a possible reduction of the number of injected antibodies should not affect substantially the treatment efficacy.

[1]  Lieping Chen,et al.  Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. , 2002, Cancer research.

[2]  Lieping Chen,et al.  Improving efficacy of interleukin‐12‐transfected dendritic cells injected into murine colon cancer with anti‐CD137 monoclonal antibodies and alloantigens , 2004, International journal of cancer.

[3]  G. Zhu,et al.  CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. , 2010, Blood.

[4]  M. Colombo,et al.  Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. , 2006, Cancer research.

[5]  Francesco Pappalardo,et al.  SimB16: Modeling Induced Immune System Response against B16-Melanoma , 2011, PloS one.

[6]  J. Peppard,et al.  The biological half-lives of four rat immunoglobulin isotypes. , 1980, Immunology.

[7]  I. Melero,et al.  Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. , 2011, Cancer research.

[8]  B. Sangro,et al.  Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial? , 2009, Immunotherapy.

[9]  Fumito Ito,et al.  Anti-CD137 Monoclonal Antibody Administration Augments the Antitumor Efficacy of Dendritic Cell-Based Vaccines , 2004, Cancer Research.

[10]  Y. Lotan,et al.  Clearance rates of total prostate specific antigen (PSA) after radical prostatectomy in African-Americans and Caucasians , 2002, Prostate Cancer and Prostatic Diseases.

[11]  Laird Ak DYNAMICS OF TUMOR GROWTH. , 1964 .

[12]  Francesco Pappalardo,et al.  Agent Based Modeling of Lung Metastasis-Immune System Competition , 2009, ICARIS.

[13]  W. Clark,et al.  The developmental biology of primary human malignant melanomas. , 1975, Seminars in oncology.

[14]  Drew M. Pardoll,et al.  Immunostimulatory monoclonal antibodies for cancer therapy , 2007, Nature Reviews Cancer.

[15]  I. Melero,et al.  Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. , 2008, Trends in pharmacological sciences.

[16]  Lieping Chen,et al.  Palettes of Vaccines and Immunostimulatory Monoclonal Antibodies for Combination , 2009, Clinical Cancer Research.

[17]  Francesco Pappalardo,et al.  Modeling the competition between lung metastases and the immune system using agents , 2010, BMC Bioinformatics.

[18]  D. Kirschner,et al.  A methodology for performing global uncertainty and sensitivity analysis in systems biology. , 2008, Journal of theoretical biology.

[19]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[20]  J. Heath Biology of the Cell Cycle , 2008 .

[21]  Lieping Chen,et al.  Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ , 2010, Cancer Immunology, Immunotherapy.

[22]  D. Pardoll T cells take aim at cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.